The Valuation of Private Investments Across Illiquid Asset Classes

What this whitepaper covers

A 28-page operator-grade guide to fair-value measurement of illiquid private investments, written for the two- or three-person back office of a $50M-to-$1B private fund. Covers the framework, the guidance stack, per-asset-class methodology, and the audit playbook. Reflects the 2024-2026 shifts in auditing standards, PCAOB inspections, SEC priorities, and market events (venture reset, office real estate repricing, private credit scrutiny).

Key takeaways

• Fair value is an exit price, not a hold-to-maturity view. ASC 820 defines fair value from the perspective of market participants in the principal market, as of the measurement date. Manager intent to hold is irrelevant to the mark. Every asset class in the whitepaper is an application of this single standard.
• The guidance stack is settled and audit firms accept it. ASC 946 requires investment companies to carry everything at fair value. ASC 820 defines what fair value means. The AICPA's 2019 Valuation Guide (roughly 700 pages) provides the operational how-to. IPEV Guidelines run in parallel for international consistency. Auditing standards AS 2501 and SAS 143-145 determine how the result gets challenged.
• The practical bar has risen since 2023. Rewritten auditing standards for estimates push auditors to challenge assumptions, not merely recompute models. PCAOB inspections punish firms that accept thin support. SEC exams keep difficult-to-value assets on annual priority lists. Private credit marks are on official-sector notice.
• Every asset class follows the same disciplines with different methods. Venture: last round, backsolve, and calibration. Private equity: calibrated multiples, the value bridge, continuation vehicles. Real estate: appraisals, cap rates, and marking the debt as well as the asset. Private debt performing: yield analysis and spread calibration. Distressed credit: recovery analysis, collateral value, static pool modeling. Esoteric assets: mortality-based DCF for life settlements; litigation finance, royalties, and GP stakes each have their own toolkit.
• The NAV practical expedient sits outside the hierarchy. Fund-of-funds interests measured at NAV under ASU 2015-07 aren't Level 3 — they're a reconciling item. Understanding this distinction shapes disclosures and audit focus.
• A proportionate valuation policy is a commercial asset. Genuine separation between deal team and final approval, calibration schedules maintained as a habit, backtesting files, targeted third-party support, and a January calendar that finishes marks before fieldwork begins — that's the whole playbook. It's within reach of a two-or-three-person back office.
• A valuation process that stands up to inspection shortens operational due diligence. Secondary buyers, examiners, and allocators all reserve skepticism for private marks. Fair value done properly protects track-record credibility and reduces the year-end negotiation from process to portfolio.

Who should read this

• Emerging and mid-sized GPs running private funds ($50M–$1B AUM) whose back office is lean and whose audit shows up fast every January
• Family offices managing direct or fund-of-funds exposure to illiquid assets, where valuation quality flows through to family reporting
• RIAs launching or evaluating proprietary private-fund vehicles for clients, who need to understand what a defensible mark actually requires
• Anyone whose auditor has recently asked harder questions about assumptions, calibration evidence, or backtesting than they used to

Sections inside

1. Introduction
2. The Framework: Fair Value Under ASC 820 — the hierarchy, the guidance stack, calibration, and the NAV practical expedient
3. Venture Capital — the last round, the backsolve, and what happens when the market moves
4. Private Equity (Buyouts) — calibrated multiples, the value bridge, and continuation vehicles
5. Real Estate — appraisals, cap rates, and marking the debt as well as the asset
6. Private Debt: Performing Loans — yield analysis, spread calibration, and the scrutiny facing private credit
7. Private Debt: Non-Performing Loans and Distressed Credit — recovery analysis, collateral value, and static pool modeling
8. Life Settlements and Other Esoteric Assets — mortality-based DCF, litigation finance, royalties, and GP stakes
9. The Toolkit at a Glance — methods, tested inputs, and failure modes as a one-page reference
10. Surviving the Audit — what auditors must do, what they will ask for, and where funds get in trouble
11. What Has Changed: 2024–2026 Developments
12. Conclusion
13. References

This whitepaper is for informational and educational purposes only and does not constitute accounting, legal, tax or investment advice. Fair value conclusions depend on facts and circumstances; managers should consult their auditors, counsel and valuation advisors regarding their specific situations. References to standards, rules, market data and third parties are believed accurate as of mid-2026 but are subject to change and should be verified against current primary sources. Fundviews Capital is not an accounting firm and does not provide audit or attest services.